View in EDS HTML Full Text PDF Full Text

POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis.

Saved in:
Bibliographic Details
Title: POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis.
Authors: Menzies AM; Melanoma Institute Australia, NSW, Australia, and The University of Sydney, Sydney, Australia.; Royal North Shore and Mater Hospitals, The University of Sydney, Sydney, Australia., Long GV; Melanoma Institute Australia, NSW, Australia, and The University of Sydney, Sydney, Australia.; Royal North Shore and Mater Hospitals, The University of Sydney, Sydney, Australia., Kohn A; Division of Hematology/Medical Oncology, School of Medicine, Oregon Health Sciences University, Portland, Oregon, USA., Tawbi H; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Weber J; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA., Flaherty K; Massachusetts General Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA., McArthur GA; Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia., Ascierto PA; Unit of Melanoma Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy., Pfluger Y; Alexander Fleming Institute, Buenos Aires, Argentina., Lewis K; Medical Oncology, University of Colorado, Health Center, Denver, Colorado, USA., Tsai KK; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA., Hamid O; The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate Los Angeles, California, USA., Prenen H; Oncology Department, University Hospital Antwerp, Antwerp, Belgium., Fein L; Alexander Fleming Institute, Buenos Aires, Argentina., Wang E; Formerly Pfizer, New York, New York, USA., Guenzel C; Formerly Pfizer, New York, New York, USA., Zhang F; Formerly Pfizer, New York, New York, USA., Kleha JF; Formerly Pfizer, New York, New York, USA., di Pietro A; Pfizer Srl, Milan, Italy., Davies MA; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Source: Neuro-oncology advances [Neurooncol Adv] 2024 Mar 18; Vol. 6 (1), pp. vdae033. Date of Electronic Publication: 2024 Mar 18 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 101755003 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-2498 (Electronic) Linking ISSN: 26322498 NLM ISO Abbreviation: Neurooncol Adv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38725995
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Menzies+AM%22">Menzies AM</searchLink>; Melanoma Institute Australia, NSW, Australia, and The University of Sydney, Sydney, Australia.; Royal North Shore and Mater Hospitals, The University of Sydney, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Long+GV%22">Long GV</searchLink>; Melanoma Institute Australia, NSW, Australia, and The University of Sydney, Sydney, Australia.; Royal North Shore and Mater Hospitals, The University of Sydney, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Kohn+A%22">Kohn A</searchLink>; Division of Hematology/Medical Oncology, School of Medicine, Oregon Health Sciences University, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Tawbi+H%22">Tawbi H</searchLink>; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Weber+J%22">Weber J</searchLink>; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Flaherty+K%22">Flaherty K</searchLink>; Massachusetts General Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22McArthur+GA%22">McArthur GA</searchLink>; Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Ascierto+PA%22">Ascierto PA</searchLink>; Unit of Melanoma Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.<br /><searchLink fieldCode="AU" term="%22Pfluger+Y%22">Pfluger Y</searchLink>; Alexander Fleming Institute, Buenos Aires, Argentina.<br /><searchLink fieldCode="AU" term="%22Lewis+K%22">Lewis K</searchLink>; Medical Oncology, University of Colorado, Health Center, Denver, Colorado, USA.<br /><searchLink fieldCode="AU" term="%22Tsai+KK%22">Tsai KK</searchLink>; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Hamid+O%22">Hamid O</searchLink>; The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate Los Angeles, California, USA.<br /><searchLink fieldCode="AU" term="%22Prenen+H%22">Prenen H</searchLink>; Oncology Department, University Hospital Antwerp, Antwerp, Belgium.<br /><searchLink fieldCode="AU" term="%22Fein+L%22">Fein L</searchLink>; Alexander Fleming Institute, Buenos Aires, Argentina.<br /><searchLink fieldCode="AU" term="%22Wang+E%22">Wang E</searchLink>; Formerly Pfizer, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Guenzel+C%22">Guenzel C</searchLink>; Formerly Pfizer, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Zhang+F%22">Zhang F</searchLink>; Formerly Pfizer, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Kleha+JF%22">Kleha JF</searchLink>; Formerly Pfizer, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22di+Pietro+A%22">di Pietro A</searchLink>; Pfizer Srl, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Davies+MA%22">Davies MA</searchLink>; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101755003%22">Neuro-oncology advances</searchLink> [Neurooncol Adv] 2024 Mar 18; Vol. 6 (1), pp. vdae033. <i>Date of Electronic Publication: </i>2024 Mar 18 (<i>Print Publication: </i>2024).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101755003 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2632-2498 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226322498%22">26322498 </searchLink><i>NLM ISO Abbreviation: </i>Neurooncol Adv <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38725995
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/noajnl/vdae033
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: vdae033
    Titles:
      – TitleFull: POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Menzies AM
      – PersonEntity:
          Name:
            NameFull: Long GV
      – PersonEntity:
          Name:
            NameFull: Kohn A
      – PersonEntity:
          Name:
            NameFull: Tawbi H
      – PersonEntity:
          Name:
            NameFull: Weber J
      – PersonEntity:
          Name:
            NameFull: Flaherty K
      – PersonEntity:
          Name:
            NameFull: McArthur GA
      – PersonEntity:
          Name:
            NameFull: Ascierto PA
      – PersonEntity:
          Name:
            NameFull: Pfluger Y
      – PersonEntity:
          Name:
            NameFull: Lewis K
      – PersonEntity:
          Name:
            NameFull: Tsai KK
      – PersonEntity:
          Name:
            NameFull: Hamid O
      – PersonEntity:
          Name:
            NameFull: Prenen H
      – PersonEntity:
          Name:
            NameFull: Fein L
      – PersonEntity:
          Name:
            NameFull: Wang E
      – PersonEntity:
          Name:
            NameFull: Guenzel C
      – PersonEntity:
          Name:
            NameFull: Zhang F
      – PersonEntity:
          Name:
            NameFull: Kleha JF
      – PersonEntity:
          Name:
            NameFull: di Pietro A
      – PersonEntity:
          Name:
            NameFull: Davies MA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 18
              M: 03
              Text: 2024 Mar 18
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 2632-2498
          Numbering:
            – Type: volume
              Value: 6
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Neuro-oncology advances
              Type: main
ResultId 1